trending Market Intelligence /marketintelligence/en/news-insights/trending/nhavbqvd9e4valfogm3k4g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CAR-T therapy developer Allogene soars nearly 39% in 1st day of trading

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


CAR-T therapy developer Allogene soars nearly 39% in 1st day of trading

Allogene Therapeutics Inc. priced its IPO of 18 million shares at $18 per share to raise about $324 million in gross proceeds.

Shares of the South San Francisco, Calif.-based cancer therapy developer began trading on the Nasdaq Global Select Market under the symbol ALLO on Oct. 11. They were up by about nearly 39% to $25 per share at the close of trading Oct. 11, giving it a market cap of over $2 billion — the most for a biotechnology company since 2009, according to Bloomberg News.

Allogene intends to use the net proceeds, about $297.8 million, to advance its immuno-oncology product pipeline which includes UCART19, a chimeric antigen receptor T cell, or CAR-T, therapy for acute lymphoblastic leukemia, a cancer of the blood and bone marrow. The company's pipeline also includes ALLO-501 for treating non-Hodgkin lymphoma and ALLO-715 to treat multiple myeloma, a cancer that forms in white blood cells.

The company will also use net proceeds to expand its headquarters in South San Francisco and to pay for certain assets it acquired from Pfizer Inc. in April. Allogene will also use the proceeds for developing other new product candidates and for working capital and other general corporate purposes.

Allogene is co-founded by Arie Belldegrun — the former chairman, president and CEO of Kite Pharma Inc. — along with Kite Pharma's former executive vice president for research and development and chief medical officer, David Chang, who currently serves as president and CEO of Allogene.

Kite Pharma was bought by Gilead Sciences Inc. for nearly $12 billion in 2017.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Cowen and Co. LLC and Jefferies LLC are acting as underwriters of the IPO.

Allogene has granted the underwriters a 30-day option to buy up to an additional 2.7 million shares from the company.